Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill is the only oral GLP-1 treatment currently available.
It was approved shortly before Christmas and is now on sale nationwide.
The pill is priced significantly below injectable weight-loss drugs.
Self-paying patients can buy the starting dose for $149 per month.
Higher doses will cost up to $299 per month, while insured patients may pay from $25.
Injectable GLP-1 treatments often cost $1,000 a month or more.
Novo hopes the pill will attract patients seeking needle-free treatment.
The launch accelerates competition with rivals such as Eli Lilly.
Novo’s shares rose after the announcement despite recent profit warnings.
The pill is currently approved only in the US, with UK approval pending.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
Craze News delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:
© 2026 Craze News. All Rights Reserved.